Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05431387 · ClinicalTrials.gov registry record · Phase 2
A Study of Cytisinicline for Vaping Cessation in Adult Smokers
A Phase 2 study, sponsored by Achieve Life Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT05431387 is a Phase 2 study that has completed, run by Achieve Life Sciences. The registered enrollment target is 160 participants.
The verdict
NCT05431387, a Phase 2 study, has completed, sponsored by Achieve Life Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.
Interventions
- DRUG Placebo
- BEHAVIORAL Behavioral support
- DRUG cytisinicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2022-07-13 |
| Est. Completion | 2023-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05431387
The ClinicalTrials.gov registry entry for NCT05431387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Achieve Life Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05431387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05431387 about?
NCT05431387 is a clinical study titled "A Study of Cytisinicline for Vaping Cessation in Adult Smokers". This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.
What is the current status of trial NCT05431387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2022-07-13. Estimated completion is 2023-02-28.
What interventions are being tested in trial NCT05431387?
The interventions under investigation include: Placebo (DRUG), Behavioral support (BEHAVIORAL), cytisinicline (DRUG).
Who is sponsoring clinical trial NCT05431387?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.